Rossella Marcucci

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2178964/publications.pdf

Version: 2024-02-01

242	12,033	44444	35168
papers	citations	50 h-index	102 g-index

246	246	246	12719
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	â€œTailoredâ€•antiplatelet bridging therapy with cangrelor: moving toward personalized medicine. Platelets, 2022, 33, 687-691.	1.1	6
2	Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID Register. Internal and Emergency Medicine, 2022, , 1.	1.0	11
3	Factors associated with persistence of symptoms 1 year after COVID-19: A longitudinal, prospective phone-based interview follow-up cohort study. European Journal of Internal Medicine, 2022, 97, 36-41.	1.0	58
4	Outcomes of Left Main Revascularization after Percutaneous Intervention or Bypass Surgery. Journal of Interventional Cardiology, 2022, 2022, 1-9.	0.5	4
5	Anti-SARS-CoV-2 vaccination does not influence anticoagulation levels in stable long-term warfarin treatment.. Blood Transfusion, 2022, , .	0.3	1
6	Antithrombotic treatment of retinal vein occlusion: a position statement from the Italian Society on Thrombosis and Haemostasis (SISET).. Blood Transfusion, 2022, , .	0.3	2
7	Can CHA2DS2-VASc and HASâ€“BLED Foresee the Presence of Cerebral Microbleeds, Lacunar and Non-Lacunar Infarcts in Elderly Patients With Atrial Fibrillation? Data From Stratâ€“AF Study. Frontiers in Neurology, 2022, 13, .	1.1	1
8	Detection of Platelet-Activating Antibodies Associated with Vaccine-Induced Thrombotic Thrombocytopenia by Flow Cytometry: An Italian Experience. Viruses, 2022, 14, 1133.	1.5	3
9	Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. Internal and Emergency Medicine, 2021, 16, 379-387.	1.0	21
10	Plasma PCSK9 levels and sepsis severity: an early assessment in the emergency department. Clinical and Experimental Medicine, 2021, 21, 101-107.	1.9	14
11	Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. Thrombosis and Haemostasis, 2021, 121, 1054-1065.	1.8	87
12	Predictors of mortality and adverse events in patients with infective endocarditis: a retrospective real world study in a surgical centre. BMC Cardiovascular Disorders, 2021, 21, 28.	0.7	15
13	Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. Internal and Emergency Medicine, 2021, 16, 1583-1591.	1.0	9
14	Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study. Internal and Emergency Medicine, 2021, 16, 2063-2068.	1.0	5
15	WT1 Expression Levels Combined with Flow Cytometry Blast Counts for Risk Stratification of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biomedicines, 2021, 9, 387.	1.4	9
16	Incidence of deep vein thrombosis through an ultrasound surveillance protocol in patients with COVID-19 pneumonia in non-ICU setting: A multicenter prospective study. PLoS ONE, 2021, 16, e0251966.	1.1	20
17	Effects of vegetarian versus Mediterranean diet on kidney function: Findings from the CARDIVEG study. European Journal of Clinical Investigation, 2021, 51, e13576.	1.7	6
18	Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines. Internal and Emergency Medicine, 2021, 16, 1113-1119.	1.0	28

#	Article	IF	Citations
19	Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. Journal of Healthcare Engineering, 2021, 2021, 1-10.	1.1	2
20	Lipid and metabolite correlation networks specific to clinical and biochemical covariate show differences associated with sexual dimorphism in a cohort of nonagenarians. GeroScience, 2021, , 1.	2.1	2
21	Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome. Haematologica, 2021, 106, 3034-3045.	1.7	24
22	Predicting Mortality Risk in Older Hospitalized Persons With COVID-19: A Comparison of the COVID-19 Mortality Risk Score with Frailty and Disability. Journal of the American Medical Directors Association, 2021, 22, 1588-1592.e1.	1.2	16
23	Updated antithrombotic strategies to reduce the burden of cardiovascular recurrences in patients with chronic coronary syndrome. Biomedicine and Pharmacotherapy, 2021, 140, 111783.	2.5	0
24	Analysis of Metabolite and Lipid Association Networks Reveals Molecular Mechanisms Associated with 3-Month Mortality and Poor Functional Outcomes in Patients with Acute Ischemic Stroke after Thrombolytic Treatment with Recombinant Tissue Plasminogen Activator. Journal of Proteome Research, 2021, 20, 4758-4770.	1.8	8
25	Sex-related differences in ventricular remodeling after myocardial infarction. International Journal of Cardiology, 2021, 339, 62-69.	0.8	11
26	Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian Society for the Study of Haemostasis and Thrombosis (SISET). Blood Transfusion, 2021, 19, 281-283.	0.3	24
27	A case of vaccine-induced immune thrombotic thrombocytopenia with massive artero-venous thrombosis. Blood Transfusion, 2021, 19, 343-346.	0.3	4
28	Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. International Journal of Cardiology, 2021, 345, 7-13.	0.8	35
29	Diffuse prothrombotic syndrome after ChAdOx1 nCoV-19 vaccine administration: a case report. Journal of Medical Case Reports, 2021, 15, 496.	0.4	11
30	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. Circulation, 2021, 144, 1323-1343.	1.6	35
31	Heparin induced thrombocytopenia: position paper from the Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfusion, 2021, 19, 14-23.	0.3	4
32	760 Prevalence of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: insights from the start-antiplatelet registry. European Heart Journal Supplements, 2021, 23, .	0.0	0
33	Management of oral anticoagulation in very old patients with non valvular atrial fibrillation related acute ischemic stroke. Journal of Thrombosis and Thrombolysis, 2020, 49, 86-93.	1.0	7
34	Prognostic relevance of GRACE risk score in Takotsubo syndrome. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 721-728.	0.4	16
35	Influence of a 3-month low-calorie Mediterranean diet compared to the vegetarian diet on human gut microbiota and SCFA: the CARDIVEG Study. European Journal of Nutrition, 2020, 59, 2011-2024.	1.8	94
36	Circulating endothelial and progenitor cells in age-related macular degeneration. European Journal of Ophthalmology, 2020, 30, 956-965.	0.7	1

#	Article	IF	Citations
37	Effects of a dietary intervention with Mediterranean and vegetarian diets on hormones that influence energy balance: results from the CARDIVEG study. International Journal of Food Sciences and Nutrition, 2020, 71, 362-369.	1.3	10
38	Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 203-210.	1.4	69
39	Prevalence and Impact of Nonalcoholic Fatty Liver Disease in Atrial Fibrillation. Mayo Clinic Proceedings, 2020, 95, 513-520.	1.4	11
40	Optimal Medical Therapy on Top of Dual-Antiplatelet Therapy: 1-Year Clinical Outcome in Patients With Acute Coronary Syndrome: The START Antiplatelet Registry. Angiology, 2020, 71, 235-241.	0.8	3
41	Differential Network Analysis Reveals Metabolic Determinants Associated with Mortality in Acute Myocardial Infarction Patients and Suggests Potential Mechanisms Underlying Different Clinical Scores Used To Predict Death. Journal of Proteome Research, 2020, 19, 949-961.	1.8	27
42	Clinical risk score to predict in-hospital mortality in COVID-19 patients: a retrospective cohort study. BMJ Open, 2020, 10, e040729.	0.8	62
43	Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1899-1913.	1.1	137
44	Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence. Archives of Cardiovascular Diseases, 2020, 113, 642-651.	0.7	9
45	Platelet Reactivity in Hepatitis C Virusâ€“Infected Patients on Dual Antiplatelet Therapy for Acute Coronary Syndrome. Journal of the American Heart Association, 2020, 9, e016441.	1.6	7
46	Health profiles and socioeconomic characteristics of nonagenarians residing in Mugello, a rural area in Tuscany (Italy). BMC Geriatrics, 2020, 20, 289.	1.1	2
47	Sanger Validation of High-Throughput Sequencing in Genetic Diagnosis: Still the Best Practice?. Frontiers in Genetics, 2020, 11, 592588.	1.1	20
48	Association Between Motor and Cognitive Performances in Elderly With Atrial Fibrillation: Strat-AF Study. Frontiers in Neurology, 2020, 11, 571978.	1.1	6
49	Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: A multicentre cohort study. British Journal of Clinical Pharmacology, 2020, 86, 2455-2463.	1.1	24
50	Sars-CoV-2 Induced Coagulopathy and Prognosis in Hospitalized Patients: A Snapshot from Italy. Thrombosis and Haemostasis, 2020, 120, 1233-1236.	1.8	15
51	Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. Clinical Pharmacology and Therapeutics, 2020, 108, 1067-1077.	2.3	32
52	Clinical Implications of â€œTailoredâ€•Antiplatelet Therapy in Patients With Chronic Total Occlusion. Journal of the American Heart Association, 2020, 9, e014676.	1.6	9
53	DOAC plasma levels measured by chromogenic antiâ€Xa assays and HPLCâ€UV in apixabanâ€•and rivaroxabanâ€treated patients from the STARTâ€Register. International Journal of Laboratory Hematology, 2020, 42, 214-222.	0.7	18
54	Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. European Heart Journal, 2020, 41, 1439-1447.	1.0	108

#	Article	IF	Citations
55	Genetic and nutritional factors determining circulating levels of lipoprotein(a): results of the â€œMontignoso Studyâ€. Internal and Emergency Medicine, 2020, 15, 1239-1245.	1.0	1
56	Muscle strength is related to mental and physical quality of life in the oldest old. Archives of Gerontology and Geriatrics, 2020, 89, 104109.	1.4	35
57	RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies. Vascular Pharmacology, 2020, 135, 106805.	1.0	39
58	COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfusion, 2020, 18, 167-169.	0.3	247
59	Semi-quantitative ultrasound assessment of nonalcoholic fatty liver disease highlightens early subclinical atherosclerotic vascular damage: From risk factors to vascular damage. Polish Annals of Medicine, 2020, , .	0.3	1
60	Results of comprehensive cardiovascular diagnostic work-up in HIV positive patients. Infezioni in Medicina, 2020, 28, 397-406.	0.7	0
61	Role of lipoprotein (a) and LPA KIV2 repeat polymorphism in bicuspid aortic valve stenosis and calcification: a proof of concept study. Internal and Emergency Medicine, 2019, 14, 45-50.	1.0	14
62	Gender-Related Differences in Antiplatelet Therapy and Impact on 1-Year Clinical Outcome in Patients Presenting With ACS: The START ANTIPLATELET Registry. Angiology, 2019, 70, 257-263.	0.8	21
63	Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry. PLoS ONE, 2019, 14, e0219676.	1.1	16
64	Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry. Journal of the American Heart Association, 2019, 8, e012596.	1.6	23
65	Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). American Journal of Cardiology, 2019, 124, 1662-1668.	0.7	20
66	Role of Biological Markers for Cerebral Bleeding Risk STRATification in Patients with Atrial Fibrillation on Oral Anticoagulants for Primary or Secondary Prevention of Ischemic Stroke (Strat-AF) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.8	6
67	Tight systolic blood pressure control with combination therapy decreases type 2 endoleaks in patients undergoing endovascular aneurysm repair. International Journal of Cardiology, 2019, 285, 97-102.	0.8	1
68	Association of Body Fat With Health-Related Quality of Life and Depression in Nonagenarians: The Mugello Study. Journal of the American Medical Directors Association, 2019, 20, 564-568.	1.2	36
69	CLOCK gene polymorphisms and quality of aging in a cohort of nonagenarians â€“ The MUGELLO Study. Scientific Reports, 2019, 9, 1472.	1.6	17
70	NMR-based metabolomics identifies patients at high risk of death within two years after acute myocardial infarction in the AMI-Florence II cohort. BMC Medicine, 2019, 17, 3.	2.3	66
71	Prognostic value of sepsis-induced coagulation abnormalities: an early assessment in the emergency department. Internal and Emergency Medicine, 2019, 14, 459-466.	1.0	16
72	Relation between postâ€myocardial infarct remodelling and gelatinase activity in patients enrolled in the TIPTOP trial. European Journal of Heart Failure, 2019, 21, 127-129.	2.9	1

#	Article	IF	Citations
73	Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nature Reviews Cardiology, 2019, 16, 113-130.	6.1	73
74	Low-Calorie Vegetarian Versus Mediterranean Diets for Reducing Body Weight and Improving Cardiovascular Risk Profile. Circulation, 2018, 137, 1103-1113.	1.6	186
75	Sex-related differences in chronic heart failure. International Journal of Cardiology, 2018, 255, 145-151.	0.8	41
76	The impact of gender on mortality after NSTEMI. Internal and Emergency Medicine, 2018, 13, 269-271.	1.0	0
77	Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end pointsâ€"Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). American Heart Journal, 2018, 198, 152-159.	1.2	24
78	The importance of integrated left atrial evaluation: From hypertension to heart failure with preserved ejection fraction. International Journal of Clinical Practice, 2018, 72, e13050.	0.8	18
79	Arterial hypertension and atrial fibrillation. Journal of Cardiovascular Medicine, 2018, 19, 51-61.	0.6	4
80	Relationship between CHA 2 DS 2 -VASc score, coronary artery disease severity, residual platelet reactivity and long-term clinical outcomes in patients with acute coronary syndrome. International Journal of Cardiology, 2018, 262, 9-13.	0.8	18
81	Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry. Angiology, 2018, 69, 795-802.	0.8	35
82	Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. Data in Brief, 2018, 17, 830-836.	0.5	5
83	Role of TGFBR1 and TGFBR2 genetic variants in Marfan syndrome. Journal of Vascular Surgery, 2018, 68, 225-233.e5.	0.6	18
84	Myocardial 123I-metaiodobenzylguanidine imaging in hypertension and left ventricular hypertrophy. Journal of Nuclear Cardiology, 2018, 25, 461-470.	1.4	1
85	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. Atherosclerosis, 2018, 277, 413-418.	0.4	48
86	Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. International Journal of Cardiology, 2018, 264, 58-63.	0.8	69
87	Impact of Chronic Renal Failure on Ischemic and Bleeding Events at 1 Year in Patients With Acute Coronary Syndrome (from the Multicenter START ANTIPLATELET Registry). American Journal of Cardiology, 2018, 122, 936-943.	0.7	12
88	On-Treatment Platelet Reactivity is a Predictor of Adverse Events in Peripheral Artery Disease Patients Undergoing Percutaneous Angioplasty. European Journal of Vascular and Endovascular Surgery, 2018, 56, 545-552.	0.8	10
89	Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL. Blood Transfusion, 2018, 16, 462-470.	0.3	54
90	Resistant hypertension: an overview. Minerva Cardiology and Angiology, 2018, 66, 337-348.	0.4	5

#	Article	IF	Citations
91	The left atrial appendage: from embryology to prevention of thromboembolism. European Heart Journal, 2017, 38, ehw159.	1.0	53
92	A khorasan wheat-based replacement diet improves risk profile of patients with type 2 diabetes mellitus (T2DM): a randomized crossover trial. European Journal of Nutrition, 2017, 56, 1191-1200.	1.8	35
93	Toward an international consensusâ€"Integrating lipoprotein apheresis and new lipid-lowering drugs. Journal of Clinical Lipidology, 2017, 11, 858-871.e3.	0.6	105
94	Lipoprotein(a) as a Risk Factor for Venous Thromboembolism: A Systematic Review and Meta-analysis of the Literature. Seminars in Thrombosis and Hemostasis, 2017, 43, 614-620.	1.5	55
95	Validation of a literature-based adherence score to Mediterranean diet: the MEDI-LITE score. International Journal of Food Sciences and Nutrition, 2017, 68, 757-762.	1.3	113
96	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). Atherosclerosis Supplements, 2017, 29, 11-16.	1.2	53
97	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. Atherosclerosis Supplements, 2017, 29, 17-24.	1.2	65
98	APpropriateness Assessment in Antiplatelet THerapY (APATHY) registry: Insight from current clinical practice. International Journal of Cardiology, 2017, 244, 13-16.	0.8	6
99	Cardiovascular benefits from ancient grain bread consumption: findings from a double-blinded randomized crossover intervention trial. International Journal of Food Sciences and Nutrition, 2017, 68, 97-103.	1.3	21
100	An Unresolved Question. JACC: Cardiovascular Interventions, 2017, 10, 2557-2559.	1.1	0
101	Erythrocyte Membrane Fluidity Alterations in Sudden Sensorineural Hearing Loss Patients: The Role of Oxidative Stress. Thrombosis and Haemostasis, 2017, 117, 2334-2345.	1.8	24
102	Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome. PLoS ONE, 2017, 12, e0186961.	1.1	21
103	Clinical events beyond one year after an acute coronary syndrome: insights from the RECLOSE 2-ACS study. EuroIntervention, 2017, 12, 2018-2024.	1.4	13
104	Symptomatic efficacy of buckwheat products in Non-Celiac Gluten Sensitivity (NCGS). Asia Pacific Journal of Clinical Nutrition, 2017, 26, 630-636.	0.3	8
105	Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Thrombosis and Haemostasis, 2016, 115, 823-825.	1.8	32
106	Apolipoprotein(a) Kringle-IV Type 2 Copy Number Variation Is Associated with Venous Thromboembolism. PLoS ONE, 2016, 11, e0149427.	1.1	24
107	Bleeding events and maintenance dose of prasugrel: BLESS pilot study. Open Heart, 2016, 3, e000460.	0.9	8
108	Increased homocysteine and lipoprotein(a) levels highlight systemic atherosclerotic burden in patients with a history of acute coronary syndromes. Journal of Vascular Surgery, 2016, 64, 163-170.	0.6	16

#	Article	IF	Citations
109	Erythrocyte oxidative stress is associated with cell deformability in patients with retinal vein occlusion. Journal of Thrombosis and Haemostasis, 2016, 14, 2287-2297.	1.9	42
110	Residual thrombin potential predicts cardiovascular death in acute coronary syndrome patients undergoing percutaneous coronary intervention. Thrombosis Research, 2016, 147, 52-57.	0.8	20
111	Intracerebral hemorrhage score in patients with spontaneous intracerebral hemorrhage pretreated and not treated with antithrombotics. Neurology and Clinical Neuroscience, 2016, 4, 169-175.	0.2	2
112	Mediterranean versus vegetarian diet for cardiovascular disease prevention (the CARDIVEG study): study protocol for a randomized controlled trial. Trials, 2016, 17, 233.	0.7	26
113	High on-aspirin platelet reactivity predicts cardiac death in acute coronary syndrome patients undergoing PCI. European Journal of Internal Medicine, 2016, 30, 49-54.	1.0	17
114	On-treatment platelet reactivity: State of the art and perspectives. Vascular Pharmacology, 2016, 77, 8-18.	1.0	19
115	Detrimental effects of niacin/laropiprant on microvascular reactivity and red cell deformability in patients with elevated lipoprotein(a) levels. Journal of Thrombosis and Thrombolysis, 2016, 41, 433-435.	1.0	3
116	Resistance to antiplatelet drugs. Can it be assessed?. IJC Metabolic & Endocrine, 2015, 8, 31-33.	0.5	2
117	Inflammatory and Antioxidant Pattern Unbalance in â€œClopidogrel-Resistantâ€•Patients during Acute Coronary Syndrome. Mediators of Inflammation, 2015, 2015, 1-12.	1.4	17
118	Management of antithrombotic therapy in patients undergoing electrophysiological device surgery. Europace, 2015, 17, 840-854.	0.7	28
119	Ticagrelor Crushed Tablets Administration in STEMI Patients. Journal of the American College of Cardiology, 2015, 65, 511-512.	1.2	167
120	Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) study. Journal of Thrombosis and Thrombolysis, 2015, 40, 76-82.	1.0	27
121	Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus. International Journal of Cardiology, 2015, 201, 561-567.	0.8	7
122	A time course study of high on treatment platelet reactivity in acute coronary syndrome male patients on dual antiplatelet therapy. Thrombosis Research, 2015, 136, 613-619.	0.8	4
123	Bleeding and stent thrombosis on P2Y₁₂-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. European Heart Journal, 2015, 36, 1762-1771.	1.0	297
124	Dual antiplatelet therapy tailored on platelet function test after coronary stent implantation: a real-world experience. Internal and Emergency Medicine, 2015, 10, 805-814.	1.0	6
125	Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2015, 8, 1563-1570.	1.1	23
126	Non-traumatic splenic rupture on dual antiplatelet therapy with aspirin and ticagrelor after stenting for acute coronary syndrome. Journal of Cardiology Cases, 2015, 12, 65-67.	0.2	7

#	Article	IF	Citations
127	Pharmacogenomics of Clopidogrel. , 2014, , 509-541.		1
128	Oxidative Modification of Fibrinogen Is Associated With Altered Function and Structure in the Subacute Phase of Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1355-1361.	1.1	77
129	Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status. Journal of Thrombosis and Thrombolysis, 2014, 37, 427-434.	1.0	7
130	Gender and Anti-thrombotic Therapy: from Biology to Clinical Implications. Journal of Cardiovascular Translational Research, 2014, 7, 72-81.	1.1	9
131	Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: The Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study. American Heart Journal, 2014, 167, 909-914.	1.2	48
132	Residual perfusion defects in patients with pulmonary embolism are related to impaired fibrinolytic capacity. Thrombosis Research, 2014, 134, 737-741.	0.8	18
133	Global platelet hyperreactivity and elevated C-reactive protein levels predict long term mortality in STEMI patients. Thrombosis Research, 2014, 134, 884-888.	0.8	16
134	Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A â€˜state-of-the-artâ€™ paper. European Heart Journal, 2014, 35, 2213-2223.	1.0	78
135	Switching from clopidogrel to prasugrel in patients having coronary stent implantation. Journal of Thrombosis and Thrombolysis, 2014, 38, 395-401.	1.0	9
136	Effects of cryoablation and radiofrequency ablation on endothelial and blood clotting activation. Internal and Emergency Medicine, 2014, 9, 853-860.	1.0	3
137	Residual platelet reactivity and outcomes with 5mg prasugrel therapy in elderly patients undergoing percutaneous coronary intervention. International Journal of Cardiology, 2014, 176, 874-877.	0.8	8
138	Hyperhomocysteinemia in patients with pulmonary embolism is associated with impaired plasma fibrinolytic capacity. Journal of Thrombosis and Thrombolysis, 2014, 38, 45-49.	1.0	10
139	Adherence to lifestyle modifications after a cardiac rehabilitation program and endothelial progenitor cells. Thrombosis and Haemostasis, 2014, 112, 196-204.	1.8	7
140	Bioequivalence in the Real World Is a Complex Challenge. Journal of the American College of Cardiology, 2013, 61, 594-595.	1.2	14
141	Prothrombotic burden in a patient with recurrent thrombotic events: might an early assessment of thrombophilia be useful in the presence of a strong family history for vascular events?. Internal and Emergency Medicine, 2013, 8, 543-545.	1.0	0
142	Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. Journal of the American College of Cardiology, 2013, 62, 2261-2273.	1.2	807
143	Platelet and leukocyte ROS production and lipoperoxidation are associated with high platelet reactivity in Non-ST elevation myocardial infarction (NSTEMI) patients on dual antiplatelet treatment. Atherosclerosis, 2013, 231, 392-400.	0.4	43
144	Impact of a cardiac rehabilitation program and inflammatory state on endothelial progenitor cells in acute coronary syndrome patients. International Journal of Cardiology, 2013, 167, 1854-1859.	0.8	40

#	Article	IF	Citations
145	Pantoprazole significantly interferes with antiplatelet effect of clopidogrel: Results of a pilot randomized trial. International Journal of Cardiology, 2013, 167, 2177-2181.	0.8	26
146	Comparison of the Degree of Platelet Aggregation Inhibition With Prasugrel Versus Clopidogrel and Clinical Outcomes in Patients With Unprotected Left Main Disease Treated With Everolimus-Eluting Stents. American Journal of Cardiology, 2013, 112, 1843-1848.	0.7	7
147	High-Dose Atorvastatin on the Pharmacodynamic Effects of Double-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Interventions. JACC: Cardiovascular Interventions, 2013, 6, 169-179.	1.1	23
148	Comparison of Prasugrel and Ticagrelor Loading Doses in ST-Segment Elevation Myocardial Infarction Patients. Journal of the American College of Cardiology, 2013, 61, 1601-1606.	1.2	403
149	Evaluation of the prevalence of severe hyperhomocysteinemia in adult patients with thrombosis who underwent screening for thrombophilia. Thrombosis Research, 2013, 132, 681-684.	0.8	16
150	Reticulated platelets predict cardiovascular death in acute coronary syndrome patients. Thrombosis and Haemostasis, 2013, 109, 846-853.	1.8	119
151	Personalized antiplatelet therapy in acute coronary syndromes: a dead-end street or a future scenario?. Interventional Cardiology, 2013, 5, 601-604.	0.0	0
152	Fibrinolytic inhibitors and fibrin characteristics determine a hypofibrinolytic state in patients with pulmonary embolism. Thrombosis and Haemostasis, 2013, 109, 565-567.	1.8	6
153	Current status of clopidogrel pharmacogenomics. Pharmacogenomics, 2012, 13, 1671-1674.	0.6	8
154	The Thrombophilic Pattern of Different Clinical Manifestations of Venous Thromboembolism: A Survey of 443 Cases of Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2012, 38, 230-234.	1.5	18
155	Atrial septal defect closure and de novo migraine: Exclusive ticlopidine efficacy. Cephalalgia, 2012, 32, 1144-1146.	1.8	5
156	Antiplatelets in acute coronary syndrome: personal perspectives. Expert Review of Cardiovascular Therapy, 2012, 10, 1487-1496.	0.6	8
157	A hypercoagulable and hypofibrinolytic state is detectable by global methods in patients with retinal vein occlusion. Atherosclerosis, 2012, 224, 97-101.	0.4	11
158	High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers. Platelets, 2012, 23, 586-593.	1.1	18
159	Diabetes and sex: from pathophysiology to personalized medicine. Internal and Emergency Medicine, 2012, 7, 215-219.	1.0	25
160	Impact of Platelet Reactivity on Clinical Outcomes After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2011, 58, 1945-1954.	1.2	383
161	Lifestyle modifi cations after acute coronary syndromes in a subset of the AMI-Florence 2 Registry. Acta Cardiologica, 2011, 66, 791-796.	0.3	6
162	Light Transmittance Aggregometry Induced by Different Concentrations of Adenosine Diphosphate to Monitor Clopidogrel Therapy: A Methodological Study. Therapeutic Drug Monitoring, 2011, 33, 94-98.	1.0	16

#	Article	IF	Citations
163	ATHEROSCLEROTIC AND THROMBOPHILIC RISK FACTORS IN PATIENTS WITH ISCHEMIC CENTRAL RETINAL VEIN OCCLUSION. Retina, 2011, 31, 724-729.	1.0	29
164	Retinal vein occlusions: a review for the internist. Internal and Emergency Medicine, 2011, 6, 307-314.	1.0	55
165	High Residual Platelet Reactivity After Clopidogrel Loading and Long-term Cardiovascular Events Among Patients With Acute Coronary Syndromes Undergoing PCI. JAMA - Journal of the American Medical Association, 2011, 306, 1215.	3.8	361
166	High on-clopidogrel platelet reactivity and risk of MACE after PCI with stent implantation. Interventional Cardiology, 2010, 2, 619-621.	0.0	0
167	Determinants to optimize response to clopidogrel in acute coronary syndrome. Pharmacogenomics and Personalized Medicine, 2010, 3, 33.	0.4	17
168	High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. Thrombosis and Haemostasis, 2010, 104, 279-286.	1.8	45
169	Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thrombosis and Haemostasis, 2010, 104, 587-292.	1.8	64
170	High platelet turnover and reactivity in renal transplant recipients patients. Thrombosis and Haemostasis, 2010, 104, 804-810.	1.8	16
171	Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 393-407.	1.5	20
172	Clopidogrel non-responsiveness and risk of cardiovascular morbidity. Thrombosis and Haemostasis, 2010, 103, 00-00.	1.8	177
173	Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate. Journal of the American College of Cardiology, 2010, 56, 919-933.	1.2	1,058
174	High lipoprotein (a) levels are associated with an increased risk of retinal vein occlusion. Atherosclerosis, 2010, 210, 278-281.	0.4	29
175	S38G single-nucleotide polymorphism at the KCNE1 locus is associated with heart failure. Heart Rhythm, 2010, 7, 363-367.	0.3	18
176	Drug and Medical Device Interactions: Stent Thrombosis and Personalizing Clopidogrel Therapy. Current Pharmacogenomics and Personalized Medicine, 2010, 8, 124-138.	0.2	2
177	Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay. Circulation, 2009, 119, 237-242.	1.6	502
178	Assessment of Platelet Function on Whole Blood by Multiple Electrode Aggregometry in High-Risk Patients With Coronary Artery Disease Receiving Antiplatelet Therapy. American Journal of Clinical Pathology, 2009, 131, 834-842.	0.4	107
179	eNOSgene influences platelet phenotype in acute coronary syndrome patients on dual antiplatelet treatment. Platelets, 2009, 20, 548-554.	1.1	9
180	High Residual Platelet Reactivity After Clopidogrel Loading and Long-Term Clinical Outcome After Drug-Eluting Stenting for Unprotected Left Main Coronary Disease. Circulation, 2009, 120, 2214-2221.	1.6	114

#	Article	IF	Citations
181	Assessment of Platelet Function in Whole Blood by Multiple Electrode Aggregometry: Transport of Samples Using a Pneumatic Tube SystemThe Authorsâ€™ Reply. American Journal of Clinical Pathology, 2009, 132, 802-804.	0.4	12
182	Response to Letter Regarding Article, â€œCardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay: A 12-Month Follow-Upâ€• Circulation, 2009, 120, .	1.6	0
183	Relation of Cytochrome P450 2C19 Loss-of-Function Polymorphism to Occurrence of Drug-Eluting Coronary Stent Thrombosis. American Journal of Cardiology, 2009, 103, 806-811.	0.7	211
184	Effect of Blood Hematocrit and Erythrocyte Deformability on Adenosine 5â€²-Diphosphate Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy. American Journal of Cardiology, 2009, 104, 764-768.	0.7	24
185	Evaluation of traditional and emerging cardiovascular risk factors in patients with non-arteritic anterior ischemic optic neuropathy: a case-control study. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 693-697.	1.0	45
186	The quality of anticoagulation on functional outcome and mortality for TIA/stroke in atrial fibrillation patients. International Journal of Cardiology, 2009, 132, 109-113.	0.8	15
187	Research Highlights:CYP2C19genetic variants and clopidogrel responsiveness in acute coronary syndrome: are we ready for individualized therapy?. Pharmacogenomics, 2009, 10, 1131-1133.	0.6	0
188	Relationship between exercise capacity, endothelial progenitor cells and cytochemokines in patients undergoing cardiac rehabilitation. Thrombosis and Haemostasis, 2009, 101, 521-526.	1.8	37
189	High-Throughput Multiplex Single-Nucleotide Polymorphism (SNP) Analysis in Genes Involved in Methionine Metabolism. Biochemical Genetics, 2008, 46, 406-423.	0.8	7
190	Incidence and Clinical Impact of Dual Nonresponsiveness to Aspirin and Clopidogrel in Patients With Drug-Eluting Stents. Journal of the American College of Cardiology, 2008, 52, 734-739.	1.2	189
191	Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events â€” A meta-analysis. International Journal of Cardiology, 2008, 128, 166-171.	0.8	73
192	ADAMTS-13 activity in the presence of elevated von Willebrand factor levels as a novel mechanism of residual platelet reactivity in high risk coronary patients on antiplatelet treatment. Thrombosis Research, 2008, 123, 130-136.	0.8	13
193	Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment. Atherosclerosis, 2008, 196, 341-348.	0.4	32
194	Low vitamin B6 and folic acid levels are associated with retinal vein occlusion independently of homocysteine levels. Atherosclerosis, 2008, 198, 223-227.	0.4	43
195	NT-proBNP and the anti-inflammatory cytokines are correlated with endothelial progenitor cellsâ€™ response to cardiac surgery. Atherosclerosis, 2008, 199, 138-146.	0.4	26
196	Intensive antiplatelet therapy for reduction of ischaemic events. Lancet, The, 2008, 372, 531.	6.3	1
197	Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thrombosis and Haemostasis, 2008, 99, 930-935.	1.8	142
198	ACE Insertion/Deletion, But Not â^’240A>T Polymorphism, Modulates the Severity in Heart Failure. Journal of Investigative Medicine, 2008, 56, 1004-1010.	0.7	10

#	Article	IF	Citations
199	Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function. Thrombosis and Haemostasis, 2008, 100, 1136-1145.	1.8	41
200	Association between homocysteine, vitamin B6 concentrations and inflammation. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1728-36.	1.4	24
201	Comparison of Different Methods to Evaluate the Effect of Aspirin on Platelet Function in High-Risk Patients With Ischemic Heart Disease Receiving Dual Antiplatelet Treatment. American Journal of Clinical Pathology, 2007, 128, 143-149.	0.4	54
202	Vitamin supplementation in the secondary prevention of venous thromboembolism: about the VITRO study. Blood, 2007, 109, 5520-5520.	0.6	0
203	Cardiovascular and thrombophilic risk factors in patients with retinal artery occlusion. Blood Coagulation and Fibrinolysis, 2007, 18, 321-326.	0.5	32
204	Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenetics and Genomics, 2007, 17, 1057-1064.	0.7	204
205	Risk of bleeding in very old atrial fibrillation patients on warfarin: Relationship with ageing and CHADS2 score. Thrombosis Research, 2007, 121, 347-352.	0.8	82
206	Adherence to a healthful life attenuates lipid parameters among a healthy Italian population. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 642-648.	1.1	17
207	Lipoprotein (a) and Venous Thromboembolism in Adults: A Meta-Analysis. American Journal of Medicine, 2007, 120, 728-733.	0.6	78
208	Lone and secondary nonvalvular atrial fibrillation: Role of a genetic susceptibility. International Journal of Cardiology, 2007, 120, 59-65.	0.8	42
209	Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. Atherosclerosis, 2007, 195, e217-e223.	0.4	42
210	Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis. Journal of the American College of Cardiology, 2007, 49, 2312-2317.	1.2	607
211	Role of haemorheological factors in patients with retinal vein occlusion. Thrombosis and Haemostasis, 2007, 98, 1215-1219.	1.8	22
212	Role of C677T and A1298C MTHFR, A2756G MTR and -786 C/T eNOS Gene Polymorphisms in Atrial Fibrillation Susceptibility. PLoS ONE, 2007, 2, e495.	1.1	20
213	Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy. Thrombosis and Haemostasis, 2007, 98, 844-851.	1.8	43
214	Role of haemorheological factors in patients with retinal vein occlusion. Thrombosis and Haemostasis, 2007, 98, 1215-9.	1.8	5
215	TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit. Thrombosis Research, 2006, 118, 495-500.	0.8	18
216	Homocysteine as an emerging risk factor for cardiovascular disease in the elderly. Aging Health, 2006, 2, 983-997.	0.3	1

#	Article	IF	Citations
217	Hyperviscosity as a Possible Risk Factor for Cerebral Ischemic Complications in Atrial Fibrillation Patients. American Journal of Cardiology, 2006, 97, 1745-1748.	0.7	29
218	Usefulness of Aspirin Resistance After Percutaneous Coronary Intervention for Acute Myocardial Infarction in Predicting One-Year Major Adverse Coronary Events. American Journal of Cardiology, 2006, 98, 1156-1159.	0.7	95
219	Protein Z levels and prognosis in patients with acute coronary syndromes. Clinical Chemistry and Laboratory Medicine, 2006, 44, 1098-102.	1.4	5
220	Erythrocyte deformability and white blood cell count are associated with aspirin resistance in high-risk vascular patients. Clinical Hemorheology and Microcirculation, 2006, 35, 175-81.	0.9	25
221	High Rate of Recurrence in Renal Transplant Recipients after a First Episode of Venous Thromboembolism. Transplantation, 2005, 80, 789-793.	0.5	26
222	In vivo effect of Chianti red wine on Tissue Factor, Tissue Factor Pathway Inhibitor and Homocysteine levels. Thrombosis and Haemostasis, 2005, 94, 689-689.	1.8	2
223	High levels of homocysteine, lipoprotein (a) and plasminogen activator inhibitor-1 are present in patients with abdominal aortic aneurysm. Thrombosis and Haemostasis, 2005, 94, 1094-1098.	1.8	65
224	Endothelial Nitric Oxide Synthase â^'786T>C, but Not 894G>T and 4a4b, Polymorphism Influences Plasma Homocysteine Concentrations in Persons with Normal Vitamin Status. Clinical Chemistry, 2005, 51, 1159-1164.	1.5	29
225	Culprit Factors for the Failure of Well-Conducted Warfarin Therapy to Prevent Ischemic Events in Patients With Atrial Fibrillation. Stroke, 2005, 36, 2159-2163.	1.0	65
226	Thrombophilic risk factors for symptomatic peripheral arterial disease. Journal of Vascular Surgery, 2005, 41, 255-260.	0.6	55
227	Impaired fibrinolysis in retinal vein occlusion: a role for genetic determinants of PAI-1 levels. Thrombosis and Haemostasis, 2004, 92, 54-60.	1.8	36
228	Hyperhomocysteinemia and vitamin B6 deficiency: New risk markers for nonvalvular atrial fibrillation?. American Heart Journal, 2004, 148, 456-461.	1.2	49
229	Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. American Journal of Medicine, 2003, 115, 601-605.	0.6	91
230	Genetic determinants of fasting and post-methionine hyperhomocysteinemia in patients with retinal vein occlusion. Thrombosis Research, 2003, 110, 7-12.	0.8	38
231	Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients. Transplantation, 2003, 75, 1551-1555.	0.5	66
232	Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2002, 32, 308-311.	0.5	72
233	Cardiovascular and thrombophilic risk factors for central retinal vein occlusion. European Journal of Internal Medicine, 2002, 13, 163-169.	1.0	42
234	Thrombophilic Risk Factors in Patients with Central Retinal Vein Occlusion. Thrombosis and Haemostasis, 2001, 86, 722-726.	1.8	124

#	Article	IF	Citations
235	HIGH CYSTEINE LEVELS IN RENAL TRANSPLANT RECIPIENTS. Transplantation, 2001, 71, 746-751.	0.5	23
236	The Role of Cysteine and Homocysteine in Venous and Arterial Thrombotic Disease. American Journal of Clinical Pathology, 2001, 116, 56-60.	0.4	17
237	Tissue Factor and Homocysteine Levels in Ischemic Heart Disease Are Associated with Angiographically Documented Clinical Recurrences after Coronary Angioplasty. Thrombosis and Haemostasis, 2000, 83, 826-832.	1.8	43
238	High prevalence of mild hyperhomocysteinemia in patients with abdominal aortic aneurysm. Journal of Vascular Surgery, 2000, 32, 531-536.	0.6	92
239	Role of platelet glycoprotein PLA1/A2 polymorphism in restenosis after percutaneous transluminal coronary angioplasty. American Journal of Cardiology, 1998, 82, 524-525.	0.7	27
240	Factor II 20210 Gât'A Polymorphism Associated to Factor V Leiden. Thrombosis Research, 1998, 89, 249-252.	0.8	6
241	The High Prevalence of Thermolabile 5-10 Methylenetetrahydrofolate Reductase (MTHFR) in Italians Is not Associated to an Increased Risk for Coronary Artery Disease (CAD). Thrombosis and Haemostasis, 1998, 79, 727-730.	1.8	73
242	A comprehensive assessment of impact of aerobic exercise on vascular and liver function in 50 male athletes: A 2-year follow-up. Polish Annals of Medicine, 0, , .	0.3	0